• LAST PRICE
    2.2400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.2100/ 4
  • Ask / Lots
    2.7400/ 100
  • Open / Previous Close
    0.0000 / 2.2400
  • Day Range
    ---
  • 52 Week Range
    Low 1.3700
    High 7.8373
  • Volume
    18
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.37
TimeVolumeKOD
09:32 ET30942.32
09:38 ET2002.31
09:39 ET4002.32
09:41 ET3002.33
09:43 ET1002.34
09:45 ET10852.33
09:50 ET5002.33
09:52 ET3322.33
09:54 ET1002.32
09:56 ET11002.33
09:57 ET8002.33
09:59 ET2002.33
10:01 ET1002.31
10:06 ET31332.31
10:08 ET12022.3
10:10 ET10502.31
10:14 ET3002.31
10:17 ET2002.3
10:19 ET16032.3
10:21 ET2002.29
10:26 ET14002.3
10:30 ET2002.3
10:32 ET3992.301
10:33 ET4992.295
10:37 ET1002.29
10:42 ET16622.29
10:46 ET1502.28
10:50 ET1002.26
10:53 ET2002.27
10:57 ET2002.26
11:00 ET2002.28
11:02 ET3002.27
11:06 ET2002.26
11:09 ET2002.26
11:11 ET1002.265
11:13 ET101122.2793
11:18 ET2002.29
11:20 ET11052.29
11:26 ET2002.28
11:27 ET7002.29
11:29 ET2002.28
11:33 ET2002.28
11:36 ET1002.3
11:38 ET2002.28
11:40 ET1052.29
11:42 ET2002.28
11:44 ET1002.3
11:45 ET2002.28
11:47 ET26002.3
11:49 ET1002.28
11:54 ET2002.28
11:58 ET5002.28
12:00 ET1002.285
12:02 ET7432.28
12:05 ET1002.28
12:09 ET1002.285
12:14 ET2002.27
12:18 ET3802.27
12:21 ET2002.27
12:23 ET3002.27
12:25 ET2002.27
12:30 ET2002.27
12:34 ET1002.27
12:38 ET40042.2605
12:41 ET2002.26
12:45 ET2002.26
12:50 ET135732.26
12:54 ET5192.26
12:56 ET4002.26
12:57 ET1002.25
01:01 ET4242.25
01:06 ET13002.25
01:10 ET2002.25
01:14 ET3002.25
01:17 ET3002.25
01:21 ET2002.25
01:26 ET5002.26
01:28 ET1002.25
01:30 ET2002.25
01:33 ET2002.25
01:37 ET2002.25
01:42 ET3002.25
01:46 ET31932.25
01:50 ET2792.24
01:51 ET10002.235
01:53 ET66142.245
01:57 ET9742.25
02:02 ET3002.255
02:04 ET29402.255
02:06 ET1002.25
02:08 ET3002.255
02:09 ET3002.25
02:11 ET13792.265
02:13 ET4002.26
02:15 ET3002.26
02:18 ET2002.25
02:20 ET2002.26
02:22 ET3182.25
02:26 ET2002.25
02:29 ET3002.25
02:31 ET2002.25
02:33 ET1002.25
02:38 ET11702.26
02:40 ET7352.27
02:42 ET4002.27
02:44 ET4352.2589
02:45 ET6352.26
02:47 ET2002.25
02:49 ET2002.25
02:54 ET10302.25
02:58 ET2002.25
03:02 ET8352.26
03:05 ET2002.25
03:07 ET6352.26
03:09 ET3002.25
03:12 ET9702.26
03:14 ET6352.26
03:16 ET15052.26
03:18 ET71152.23
03:20 ET2502.24
03:21 ET10002.235
03:25 ET3002.23
03:27 ET9002.235
03:30 ET35102.245
03:32 ET22002.245
03:34 ET3002.245
03:36 ET1002.245
03:38 ET2002.24
03:41 ET20022.24
03:45 ET7532.24
03:48 ET44562.24
03:50 ET4982.23
03:52 ET1002.24
03:54 ET11822.24
03:56 ET4002.23
03:57 ET52692.24
03:59 ET8002.24
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKOD
Kodiak Sciences Inc
117.7M
-0.5x
---
United StatesTVGN
Tevogen Bio Holdings Inc
118.1M
-1,653.5x
---
United StatesNVCT
Nuvectis Pharma Inc
119.5M
-4.6x
---
United StatesRGLS
Regulus Therapeutics Inc
115.2M
-1.2x
---
United StatesCMPX
Compass Therapeutics Inc.
121.1M
-2.5x
---
United StatesCRVS
Corvus Pharmaceuticals Inc
111.3M
-3.5x
---
As of 2024-07-03

Company Information

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Contact Information

Headquarters
1200 PAGE MILL RDPALO ALTO, CA, United States 94304
Phone
650-281-0850
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Victor Perlroth
Chief Financial Officer, Executive Vice President, Secretary
John Borgeson
Lead Independent Director
Robert Profusek
Independent Director
Felix Baker
Independent Director
Charles Bancroft

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$117.7M
Revenue (TTM)
$0.00
Shares Outstanding
52.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.37
EPS
$-4.44
Book Value
$5.06
P/E Ratio
-0.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.